Find out more about MSF's operations, mission, and it's principles.
In the poorest parts of Africa and Asia this figure rises to a half of the population. We challenge the high cost of medicines and the absence of treatment for many of the diseases affecting our patients.
Too often we cannot treat patients because the medicines are too expensive, or they are no longer produced.
Sometimes, the only drugs we have are highly toxic or ineffective and nobody is looking for a better cure.
As a medical humanitarian organisation, it is fundamentally unacceptable that access to essential medicines is increasingly difficult, particularly for the most common global infectious diseases.
In response to the need for better treatments, vaccines and diagnostic tests MSF set up its Access Campaign in 1999 to improve care for patients.
The aims of MSF Access Campaign are to:
In 2003, MSF joined forces with six other organisations to establish the Drugs For Neglected Diseases Initiative (DNDi).
The aim is to develop new drugs or new formulations of existing drugs for patients suffering from the most neglected communicable diseases.
DNDi seeks to address unmet needs by taking on projects that others are unable or unwilling to pursue.
MSF is well known for its humanitarian medical work, but it has also produced important research based on its field experience with vulnerable populations.
This website archives MSF's scientific articles and makes them available free, with full text, and in an easily searchable format. MSF Field Research website.
MSF is also pushing for increased research into neglected diseases – such as tuberculosis, malaria, sleeping sickness, and leishmaniasis – through increased funding, investing in research and development (R&D) capability in developing countries, and supporting alternative models for R&D.
Some treatments are no longer produced. MSF is calling on companies and governments to find solutions to bring unprofitable but medically necessary drugs back into production.
MSF is also supporting developing countries in codifying into law the "safeguards" that are allowed under international trade rules in order to protect access to medicines.